Previous close | 19.72 |
Open | 19.87 |
Bid | 20.46 x 100 |
Ask | 20.63 x 200 |
Day's range | 19.49 - 20.83 |
52-week range | 1.16 - 24.40 |
Volume | |
Avg. volume | 430,179 |
Market cap | 538.709M |
Beta (5Y monthly) | 2.26 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.97 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.25 |
STAMFORD, Conn., May 22, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in two upcoming investor conferences in June: Jefferies Healthcare Conference - New York City, New York Fireside chat on Wednesday, June 5 at 9:00 a.m. ET44th Annual Goldman Sachs Global Healthcare Conference - Miami, Florida Fireside chat on Monday, June 10 at 3:20 p.m. ET Live and archived webc
GeneDx Holdings Corp. ( NASDAQ:WGS ) investors will be delighted, with the company turning in some strong numbers with...
GeneDx Holdings Corp. (NASDAQ:WGS) Q1 2024 Earnings Call Transcript April 29, 2024 GeneDx Holdings Corp. beats earnings expectations. Reported EPS is $-0.33, expectations were $-0.68. GeneDx Holdings Corp. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank […]